ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2021年04月28日 11時00分
Source:
Eisai
埼玉りそな銀行とエーザイ、埼玉県における認知症との共生と予防に向け業務提携を締結
認知症エコシステムの構築
東京, 2021年04月28日 - (JCN Newswire) - りそなグループの株式会社埼玉りそな銀行(本社:埼玉県、社長:福岡 聡、以下 埼玉りそな銀行)とエーザイ株式会社(本社:東京都、代表執行役CEO:内藤 晴夫、以下 エーザイ)は、埼玉県民の皆さまが末永く健康で安心して暮らせる地域社会を実現するため、本日、認知症の共生と予防に取り組むエコシステム(以下、「認知症エコシステム」)構築に向けた業務提携契約を締結したことをお知らせします。
埼玉県は全国トップクラスのスピードで高齢化が進行すると見込まれており、認知症の共生と予防に向けた取り組みが大きな課題のひとつです。埼玉りそな銀行とエーザイは、本業務提携を通じて埼玉りそな銀行が有する埼玉県内のお客さま基盤・ネットワークと、エーザイの認知症領域における創薬活動や疾患啓発活動の豊富な経験知を融合させた認知症エコシステムを構築し、県民ならびに県内企業の皆さまの健康生活のサポートおよび持続可能な地域社会づくりを行います。
その取り組みの第一弾として、埼玉りそな銀行が取り扱う投資信託「埼玉りそな・グローバルバランス・プラスESG~SaitamaDGs~」※1のご契約者さまに、エーザイのブレインパフォーマンス(脳の健康度)セルフチェックツール「のうKNOWTM」(ノウノウ、非医療機器)※2を提供します。お客さまに埼玉県債などへの投資を通じた資産形成と地域貢献の機会を提供するとともに、ブレインパフォーマンスの定期的なチェックと生活習慣の改善を通じた脳の健康維持により、安心した暮らしの実現をサポートします。
さらに、埼玉りそな銀行とエーザイは、認知症エコシステムを通じて県内自治体や企業、大学、公共機関等と連携し、県民の皆さまの不安の軽減・解消や豊かな老後生活の実現、県内企業の健康経営の実現など、持続可能な安心して暮らせる地域社会づくりに向けた価値共創をめざしてまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2021/news202132.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
ANIME TOKYO STATION ON ROBLOX: Commemorating the One-Year Anniversary with Gifts and a Wealth of Add-on Content
Jan 30, 2026 09:00 JST
MAZDA CX-5 Achieves Five Million Units in Global Production and Sales
Jan 29, 2026 16:15 JST
The Executive Centre Celebrates 25 Years in Japan: A Commitment to Long-Term Growth and Investment
Jan 29, 2026 12:00 JST
Hitachi reinvents Ellipse Enterprise Asset Management (EAM) solution with Microsoft's AI-enabled technology to improve critical infrastructure resilience
Jan 29, 2026 10:14 JST
TANAKA Recognized as a "Tokyo Sports Promotion Company" for the 11th Consecutive Year
Jan 28, 2026 22:00 JST
NTT, DOCOMO, and NTT DATA to Exhibit at MWC Barcelona 2026
Jan 28, 2026 18:29 JST
MHI Thermal Systems Receives "Minister of Economy, Trade and Industry Award" and MHI's Aerospace Parts Factory Receives "Agency for Natural Resources and Energy Commissioner's Award" at 2025 Energy Conservation Grand Prize Awards
Jan 28, 2026 18:08 JST
Mitsubishi Power Completes GTCC Upgraded Reliability Package at VPI's Damhead Creek Power Station
Jan 28, 2026 17:58 JST
Fujitsu and Tokai National Higher Education and Research System develop space weather prediction capabilities technology leveraging AI
Jan 28, 2026 10:55 JST
NEC Develops High-Efficiency, Compact Power Amplifier Module for 5G Base Station Radio Units
Jan 28, 2026 10:05 JST
Shoucheng Holdings-Backed Robotics Firms Set to Appear at 2026 CMG New Year's Gala
Jan 28, 2026 09:35 JST
The 19th Asian Financial Forum concludes successfully
Jan 27, 2026 23:27 JST
NTT DOCOMO Develops a Solution to Streamline DOOH Advertiser Review Operations
Jan 27, 2026 10:25 JST
Fujitsu launches new platform enabling autonomous operation of generative AI optimized for in-house applications in a dedicated environment
Jan 26, 2026 13:30 JST
Mitsubishi Heavy Industries and Mitsubishi Electric Invest in Japan LEO Shachu, a Space Venture Established by Mitsui & Co.
Jan 26, 2026 13:24 JST
CaoCao Inc. Ushers in China's Fully Purpose-Built Robotaxi Era, Aims to Deploy 100,000 Robotaxis by 2030
Jan 26, 2026 11:51 JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Jan 26, 2026 11:37 JST
Fujitsu to support Mizuho Financial Group's human capital disclosure with a non-financial information collection and disclosure support service
Jan 26, 2026 10:45 JST
TOYOTA GAZOO Racing Announces GR Yaris Sebastien Ogier 9x World Champion Edition
Jan 23, 2026 19:26 JST
NEC Develops New 5G Base Station Radio Unit for Enhanced Communication Throughput, Compactness, and Energy Efficiency
Jan 23, 2026 15:00 JST
More Latest Release >>
Related Release
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
1/26/2026 11:37:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
1/21/2026 4:44:00 PM JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
1/13/2026 9:50:00 AM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
1/6/2026 10:43:00 AM JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
12/11/2025 7:41:00 PM JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
12/9/2025 6:51:00 PM JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
12/4/2025 6:36:00 PM JST
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
12/3/2025 6:19:00 PM JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
12/3/2025 12:01:00 AM JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
11/28/2025 11:00:00 PM JST
More Press release >>